Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2018

01-12-2018 | ASO Author Reflections

ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time—Highest Rates of Use Now in Triple-Negative and HER2+ Disease

Authors: Brittany L. Murphy, MD MS, Judy C. Boughey, MD

Published in: Annals of Surgical Oncology | Special Issue 3/2018

Login to get access

Excerpt

Initially, neoadjuvant chemotherapy (NAC) was predominantly used in locally advanced disease.1,2 However, NAC is now considered for any patient who would be recommended adjuvant chemotherapy based on clinical and histological examination at diagnosis.2 NAC may downstage disease in both the breast and axilla, as well as allow the assessment of in vivo response to therapy.1,2 While tumor size and nodal involvement were the dominant factors in considering NAC initially, currently tumor biology is a key factor. Response rates to NAC are highest in HER2+ disease and in triple-negative breast cancer.3 Additionally, neoadjuvant endocrine therapy is increasingly considered for hormone receptor-positive disease. Our hypothesis was that use of NAC had changed over time with higher use in triple-negative and HER2+ disease than in hormone receptor (HR)+/HER2− disease. …
Literature
1.
2.
Untch M, Konecny GE, Paepke S, von Minckwitz G. Current and future role of neoadjuvant therapy for breast cancer. Breast 2014;23(5):526–37.CrossRefPubMed
3.
Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608-14; discussion 614–6.CrossRef
4.
Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol. 2018;25(8):2241–8.CrossRefPubMed
5.
Nandy A, Gangopadhyay S, Mukhopadhyay A. Individualizing breast cancer treatment: the dawn of personalized medicine. Exp Cell Res. 2014;320(1):1–11.CrossRefPubMed
Metadata
Title
ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time—Highest Rates of Use Now in Triple-Negative and HER2+ Disease
Authors
Brittany L. Murphy, MD MS
Judy C. Boughey, MD
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-7046-9

Other articles of this Special Issue 3/2018

Annals of Surgical Oncology 3/2018 Go to the issue

ASO Author Reflections

ASO Author Reflections: Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients

ASO Author Reflections

ASO Author Reflections: Salvage Surgery for Anal Cancer

ASO Author Reflections

ASO Author Reflections: Incorporating Lymphovascular Invasion to Improve the Prognostic Reliability of the T-Staging System for Adrenocortical Carcinoma—A Multicenter Study

ASO Author Reflections

ASO Author Reflections: Prognostic Nutritional Index-Based Risk Stratification for Lung Cancer

ASO Author Reflections

ASO Author Reflections: Fluorescent Anti-CEA IR800 for Tumor Labeling

ASO Author Reflections

ASO Author Reflections: Novel Robotic Training Curriculum Used in Complex Surgical Oncology